New Delhi, May 4 -- India's intellectual property (IP) framework remains compliant with global trade rules while supporting affordable healthcare worldwide, according to the Global Trade Research Initiative (GTRI).

The think tank highlighted that India supplies nearly 20 percent of the world's generic medicines, with generics typically reducing drug prices by 80-90 percent.

US Continues to Flag IP Concerns

India has once again been placed on the Priority Watch List in the 2026 Special 301 Report released by the Office of the United States Trade Representative (USTR) on April 30. The listing reflects ongoing US concerns over pharmaceutical-related IP protection and enforcement in India.

However, GTRI clarified that the Special 301 proc...